Assignee
SANGAMO THERAPEUTICS INC
US·88 granted patents·73 pending applications·178 citations·filing 2014–2025
Top patents by PatentIndex Score
161 records- 0196US10669557B2Targeted deletion of cellular DNA sequencesSANGAMO THERAPEUTICS INC·Filed 2017·Granted Jun 2, 2020·13 cites·7 claims
- 0296US10196651B2Methods and compositions for treatment of a genetic conditionSANGAMO THERAPEUTICS INC·Filed 2017·Granted Feb 5, 2019·16 cites·17 claims
- 0396US10113207B2Methods and compositions for targeted single-stranded cleavage and targeted integrationSANGAMO THERAPEUTICS INC·Filed 2017·Granted Oct 30, 2018·19 cites·12 claims
- 0495US10196652B2Methods and compositions for treatment of a genetic conditionSANGAMO THERAPEUTICS INC·Filed 2018·Granted Feb 5, 2019·11 cites·21 claims
- 0594US10293000B2Methods and compositions for the treatment of lysosomal storage diseasesSANGAMO THERAPEUTICS INC·Filed 2017·Granted May 21, 2019·10 cites·7 claims
- 0694US10066242B2Artificial nucleases comprising engineered cleavage half-domainsSANGAMO THERAPEUTICS INC·Filed 2017·Granted Sep 4, 2018·5 cites·18 claims
- 0792US11136599B2Artifical nucleases comprising engineered cleavage half-domainsSANGAMO THERAPEUTICS INC·Filed 2020·Granted Oct 5, 2021·2 cites·9 claims
- 0892US10143760B2Liver-specific constructs, factor VIII expression cassettes and methods of use thereofSANGAMO THERAPEUTICS INC·Filed 2016·Granted Dec 4, 2018·7 cites·34 claims
- 0992US9833479B2Gene correction of SCID-related genes in hematopoietic stem and progenitor cellsSANGAMO THERAPEUTICS INC·Filed 2017·Granted Dec 5, 2017·5 cites·9 claims
- 1091US10975375B2Methods and compositions for regulation of transgene expressionSANGAMO THERAPEUTICS INC·Filed 2017·Granted Apr 13, 2021·3 cites·11 claims
- 1191US10640790B2Artificial nucleases including engineered FokI cleavage half-domainsSANGAMO THERAPEUTICS INC·Filed 2018·Granted May 5, 2020·3 cites·10 claims
- 1291US10563184B2Regulation of gene expression using engineered nucleasesSANGAMO THERAPEUTICS INC·Filed 2019·Granted Feb 18, 2020·7 cites·26 claims
- 1391US10253333B2DNA-binding proteins and uses thereofSANGAMO THERAPEUTICS INC·Filed 2017·Granted Apr 9, 2019·5 cites·12 claims
- 1490US10500229B2Targeted disruption of the MHC cell receptorSANGAMO THERAPEUTICS INC·Filed 2016·Granted Dec 10, 2019·6 cites·8 claims
- 1589US11452782B2Liver-specific constructs factor VIII expression cassettes and methods of use thereofSANGAMO THERAPEUTICS INC·Filed 2018·Granted Sep 27, 2022·3 cites·26 claims
- 1689US10435677B2Genetically modified human cell with a corrected mutant sickle cell mutationSANGAMO THERAPEUTICS INC·Filed 2015·Granted Oct 8, 2019·8 cites·9 claims
- 1789US10407476B2Methods and compositions for treating hemophiliaSANGAMO THERAPEUTICS INC·Filed 2017·Granted Sep 10, 2019·4 cites·11 claims
- 1888US10968261B2Methods and compositions for genome engineeringSANGAMO THERAPEUTICS INC·Filed 2018·Granted Apr 6, 2021·2 cites·12 claims
- 1988US10265377B2Methods and compositions for treating Huntington's DiseaseSANGAMO THERAPEUTICS INC·Filed 2016·Granted Apr 23, 2019·4 cites·15 claims
- 2087US10975393B2Engineered target specific nucleasesSANGAMO THERAPEUTICS INC·Filed 2017·Granted Apr 13, 2021·2 cites·16 claims
- 2187US10808020B2Nuclease-mediated regulation of gene expressionSANGAMO THERAPEUTICS INC·Filed 2016·Granted Oct 20, 2020·6 cites·25 claims
- 2286US11981967B2Engineering AAVSANGAMO THERAPEUTICS INC·Filed 2020·Granted May 14, 2024·5 cites·20 claims
- 2386US11661612B2DNA-binding proteins and uses thereofSANGAMO THERAPEUTICS INC·Filed 2019·Granted May 30, 2023·1 cites·12 claims
- 2486US11040115B2Method for the treatment of lysosomal storage diseasesSANGAMO THERAPEUTICS INC·Filed 2019·Granted Jun 22, 2021·1 cites·7 claims
- 2586US2025129181A1T cell modifying compounds and uses thereofSANGAMO THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2686US2023414710A1Methods and compositions for treating huntington's diseaseSANGAMO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2785US11123443B2Htt repressors and uses thereofSANGAMO THERAPEUTICS INC·Filed 2019·Granted Sep 21, 2021·2 cites·9 claims
- 2885US10960085B2Modulation of liver genesSANGAMO THERAPEUTICS INC·Filed 2017·Granted Mar 30, 2021·3 cites·19 claims
- 2985US10619154B2Nuclease-mediated regulation of gene expressionSANGAMO THERAPEUTICS INC·Filed 2018·Granted Apr 14, 2020·3 cites·12 claims
- 3084US10858416B2Methods and compositions for modification of a HLA locusSANGAMO THERAPEUTICS INC·Filed 2018·Granted Dec 8, 2020·1 cites·9 claims
- 3183US10450585B2Delivery methods and compositions for nuclease-mediated genome engineeringSANGAMO THERAPEUTICS INC·Filed 2016·Granted Oct 22, 2019·6 cites·13 claims
- 3283US2024229079A9Engineered target specific nucleasesSANGAMO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3382US11235026B2Methods and compositions for modulating PD1SANGAMO THERAPEUTICS INC·Filed 2018·Granted Feb 1, 2022·1 cites·7 claims
- 3482US10828376B2Liver-specific constructs and methods of use thereofSANGAMO THERAPEUTICS INC·Filed 2018·Granted Nov 10, 2020·1 cites·13 claims
- 3581US11725192B2Separation and quantification of empty and full viral capsid particlesSANGAMO THERAPEUTICS INC·Filed 2020·Granted Aug 15, 2023·2 cites·24 claims
- 3681US2023416775A1Methods and compositions for treatment of a genetic conditionSANGAMO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3780US11725218B2Artificial nucleases comprising engineered cleavage half-domainsSANGAMO THERAPEUTICS INC·Filed 2021·Granted Aug 15, 2023·0 cites·18 claims
- 3879US10918668B2Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleasesSANGAMO THERAPEUTICS INC·Filed 2018·Granted Feb 16, 2021·1 cites·9 claims
- 3979US2022331447A1Methods of treating lysosomal storage diseasesSANGAMO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4079US2022356493A1Dna-binding proteins and uses thereofSANGAMO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4179US2022316016A1Methods and compositions for targeted single-stranded cleavage and targeted integrationSANGAMO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4278US11690921B2Delivery of target specific nucleasesSANGAMO THERAPEUTICS INC·Filed 2019·Granted Jul 4, 2023·2 cites·24 claims
- 4378US11421007B2Zinc finger protein compositions for modulation of huntingtin (Htt)SANGAMO THERAPEUTICS INC·Filed 2019·Granted Aug 23, 2022·1 cites·16 claims
- 4478US2023119850A1Liver-specific constructs, factor viii expression cassettes and methods of use thereofSANGAMO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4577US11859190B2Methods and compositions for regulation of transgene expressionSANGAMO THERAPEUTICS INC·Filed 2021·Granted Jan 2, 2024·0 cites·5 claims
- 4677US2023203540A1Methods and compositions for nuclease-mediated targeted integration of transgenes into mammalian liver cellsSANGAMO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4777US2023346844A1Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleasesSANGAMO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4877US2022396634A1T cell modifying compounds and uses thereofSANGAMO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4976US2025313848A1Engineered genetic modulatorsSANGAMO THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 5076US2021188926A1Methods and compositions for genome engineeringSANGAMO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 161 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →